Trial · NCT02722668
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
NCT02722668, Phase 2, Completed, Masonic Cancer Center, University of Minnesota; results first posted 2025-07-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep. Trials, record NCT02722668. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02722668
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
- NCT number
- NCT02722668
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 15 participants, actual
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Conditions
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Burkitt's Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Large-cell Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Marginal Zone B-cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-cell Lymphoma, Prolymphocytic Leukemia, Bone Marrow Failure Syndromes, Myeloproliferative Neoplasms/Myelofibrosis, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Leukemia or MDS in Aplasia, Relapsed T-Cell Lymphoma, Relapsed Multiple Myeloma, Plasma Cell Leukemia
- Interventions
- Fludarabine, Cyclophosphamide, MMF, Sirolimus, TBI, Umbilical cord blood cell infusion, ATG
- First posted
- 2016-03-30
- Last updated
- 2025-07-04
- Results first posted
- 2025-07-04
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Probability of Acute Graft Versus Host Disease (GVHD) | Day 100 | Simple proportions will be used to estimate the probability of grade II-IV actue GVHD. |
| Secondary | Incidence of Acute GVHD | Day 100 | Percentage of patients with grade III-IV acute GVHD. |
| Secondary | Transplant Related Mortality | 6 months post transplant | |
| Secondary | Chimerism | Day 21 | Percentage of subjects with donor chimerism. |
| Secondary | Chimerism | Day 100 | Percentage of subjects with donor chimerism. |
| Secondary | Chimerism | Day 180 | Percentage of subjects with donor chimerism. |
| Secondary | Chimerism | 1 year post transplant | Percentage of subjects with donor chimerism. |
| Secondary | Neutrophil Engraftment | Day 42 | Percentage of subjects with neutrophil engraftment. |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Probability of Acute Graft Versus Host Disease (GVHD) | Day 100 | Percent of participants | NUMBER | |
| SECONDARY | Incidence of Acute GVHD | Day 100 | Percent of participants | NUMBER | |
| SECONDARY | Transplant Related Mortality | 6 months post transplant | Percent of participants | NUMBER | |
| SECONDARY | Chimerism | Day 21 | Percentage of participants | NUMBER | |
| SECONDARY | Chimerism | Day 100 | Percentage of participants | NUMBER | |
| SECONDARY | Chimerism | Day 180 | Percentage of participants | NUMBER | |
| SECONDARY | Chimerism | 1 year post transplant | Percentage of participants | NUMBER | |
| SECONDARY | Neutrophil Engraftment | Day 42 | Percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Probability of Acute Graft Versus Host Disease (GVHD) | No Anti-thymocyte Globulin (ATG) | 0 | 95% Confidence Interval 0 to 100 | Percent of participants | |
| Probability of Acute Graft Versus Host Disease (GVHD) | Anti-thymocyte Globulin (ATG) | 30 | 95% Confidence Interval 3 to 57 | Percent of participants | |
| Incidence of Acute GVHD | No Anti-thymocyte Globulin (ATG) | 0 | 95% Confidence Interval 0 to 100 | Percent of participants | |
| Incidence of Acute GVHD | Anti-thymocyte Globulin (ATG) | 10 | 95% Confidence Interval 0 to 28 | Percent of participants | |
| Transplant Related Mortality | No Anti-thymocyte Globulin (ATG) | 20 | 95% Confidence Interval 0 to 50 | Percent of participants | |
| Transplant Related Mortality | Anti-thymocyte Globulin (ATG) | 20 | 95% Confidence Interval 0 to 44 | Percent of participants | |
| Chimerism | No Anti-thymocyte Globulin (ATG) | 64 | 95% Confidence Interval 0 to 81 | Percentage of participants | |
| Chimerism | Anti-thymocyte Globulin (ATG) | 89 | 95% Confidence Interval 0 to 100 | Percentage of participants | |
| Chimerism | No Anti-thymocyte Globulin (ATG) | 100 | 95% Confidence Interval 0 to 100 | Percentage of participants | |
| Chimerism | Anti-thymocyte Globulin (ATG) | 100 | 95% Confidence Interval 70 to 100 | Percentage of participants |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | No Anti-thymocyte Globulin (ATG) | 5 | |
| Overall Study | STARTED | Anti-thymocyte Globulin (ATG) | 10 | |
| Overall Study | COMPLETED | No Anti-thymocyte Globulin (ATG) | 5 | |
| Overall Study | COMPLETED | Anti-thymocyte Globulin (ATG) | 10 | |
| Overall Study | NOT COMPLETED | No Anti-thymocyte Globulin (ATG) | 0 | |
| Overall Study | NOT COMPLETED | Anti-thymocyte Globulin (ATG) | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | No Anti-thymocyte Globulin (ATG) | 1 | 5 |
| Total, all-cause mortality | Anti-thymocyte Globulin (ATG) | 2 | 10 |
| Total, other adverse events | No Anti-thymocyte Globulin (ATG) | 0 | 5 |
| Total, other adverse events | Anti-thymocyte Globulin (ATG) | 0 | 10 |
| Total, serious adverse events | No Anti-thymocyte Globulin (ATG) | 0 | 5 |
| Total, serious adverse events | Anti-thymocyte Globulin (ATG) | 0 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| No Anti-thymocyte Globulin (ATG) vs Anti-thymocyte Globulin (ATG): deaths from any cause | Trial comparisons |
| No Anti-thymocyte Globulin (ATG) vs Anti-thymocyte Globulin (ATG): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02722668
GET https://conductscience.org/api/trials/v1/NCT02722668/registered